Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining combination chemotherapy with radiation therapy in treating patients who have stage IIIA or stage IIIB non-small cell lung cancer.
Checked against the public recordLast updated Nov 17, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Radiation Therapy Oncology Group
- Interventions being studied
- Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel; Radiation: radiation therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed loco-regionally advanced non-small cell lung cancer meeting one of the following staging criteria: * Medically inoperable stage IIIA * Unresectable stage IIIA or IIIB * Measurable disease on three-dimensional planning CT scan * No post-resection intrathoracic tumor recurrence * No pleural effusion on chest x-ray except those occurring after attempted thoracotomy or other invasive thoracic procedure * No evidence of small cell histology * No evidence of hematogenous or distant metastases PATIENT CHARACTERISTICS: Age: * Not specified Performance status: * Zubrod 0-1 Life expectancy: * Not specified Hematopoietic: * Platelet count at least 100,000/mm\^3 * Absolute granulocyte count at least 2,000/mm\^3 * Hemoglobin at least 8.0 g/dL Hepatic: * Bilirubin no greater than 1.5 mg/dL * Serum glutamate oxaloacetate transaminase (SGOT) no greater than 1.5 times upper limit of normal (unless caused by documented benign disease) Renal: * Creatinine no greater than 1.5 mg/dL Cardiovascular: * No myocardial infarction within the past 6 months * No symptomatic heart disease, including angina, congestive heart failure, or uncontrolled arrhythmia Pulmonary: * Forced expiratory volume (FEV)\_1 greater than 1,000 mL Other: * No other invasive malignancy within the past 3 years except nonmelanoma skin cancer * No weight loss of more than 10% in 3 months prior to diagnosis * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * No prior thoracic or neck radiotherapy Surgery: * See Disease Characteristics * No prior complete or subtotal tumor resection
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- CCOP - Bay Area Tumor InstituteOakland, California
- University of Miami Sylvester Comprehensive Cancer CenterMiami, Florida
- Wendt Regional Cancer Center of Finley HospitalDubuque, Iowa
- Monmouth Medical CenterLong Branch, New Jersey
- Akron City HospitalAkron, Ohio
- Cancer Care Center, IncorporatedSalem, Ohio
- Delaware County Memorial HospitalDrexel Hill, Pennsylvania
- Dale and Frances Hughes Cancer CenterEast Stroudsburg, Pennsylvania
- Mercy Hospital of PittsburghPittsburgh, Pennsylvania
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical CenterNashville, Tennessee
- Cottonwood Hospital Medical CenterMurray, Utah
- McKay-Dee Hospital CenterOgden, Utah
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 17, 2015. Always confirm current availability with the study team.